Harshani R. Lawrence

4.5k citations

75 papers · 3.5k indexed · 1 hit paper · h-index 35

Co-authors: Nicholas J. Lawrence Saı̈d M. Sebti Wayne C. Guida M.L. Richard Yip Jie Wu Yunting Luo Michelle A. Blaskovich Kiran Mahajan
Topics: Ubiquitin and proteasome pathways (14 papers)Cancer-related Molecular Pathways (13 papers)Estrogen and related hormone effects (10 papers)
Cited by: Toxicology Oncology Immunology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Nature Communications
Partner nations: United States United Kingdom Italy

In The Last Decade

Harshani R. Lawrence

74 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

2007 616 citations Wayne C. Guida, Harshani R. Lawrence et al. profile →

Peers

Countries citing papers authored by Harshani R. Lawrence

Since Specialization

Citations

This map shows the geographic impact of Harshani R. Lawrence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harshani R. Lawrence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harshani R. Lawrence more than expected).

Fields of papers citing papers by Harshani R. Lawrence

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harshani R. Lawrence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harshani R. Lawrence. The network helps show where Harshani R. Lawrence may publish in the future.

Co-authorship network of co-authors of Harshani R. Lawrence

This figure shows the co-authorship network connecting the top 25 collaborators of Harshani R. Lawrence. A scholar is included among the top collaborators of Harshani R. Lawrence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harshani R. Lawrence. Harshani R. Lawrence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of ATP-Competitive Human CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function 2024 ·Molecular Cancer Therapeutics ·Shengyan Xiang,(unknown),(unknown),(unknown),Renan B. Ferreira,Harshani R. Lawrence,Nicholas J. Lawrence,Damon R. Reed,Mark G. Alexandrow	1
2	Delving into the reducing effects of the GABAB positive allosteric modulator, KK-92A, on alcohol-related behaviors in rats 2023 ·Alcohol ·Paola Maccioni,Katarzyna Kaczanowska,Carla Lobina,(unknown),Valentina Bassareo,Gian Luigi Gessa,Harshani R. Lawrence,Patricia McDonald,Giancarlo Colombo	3
3	TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate 2022 ·Cancer Immunology Research ·(unknown),(unknown),(unknown),John M. Koomen,Eric A. Welsh,(unknown),Sujeewa Ranatunga,Chunying Yang,(unknown),Harshani R. Lawrence,Paulo C. Rodrı́guez,Anders Berglund,John L. Cleveland	1
4	Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting 2022 ·Science Translational Medicine ·(unknown),Kiran Mahajan,Arun Renganathan,Cody Weimholt,Jingqin Luo,Vandna Kukshal,Joseph M. Jez,(unknown),Bo Zhang,Tiandao Li,Bin Fang,Yunting Luo,Nicholas J. Lawrence,Harshani R. Lawrence,Felix Y. Feng,Nupam P. Mahajan	19
5	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results 2021 ·Clinical Cancer Research ·Joseph Pidala,Kelly Walton,Hany Elmariah,Jongphil Kim,Asmita Mishra,Nelli Bejanyan,Taiga Nishihori,Farhad Khimani,Lia Perez,Rawan Faramand,Marco L. Davila,Michael L. Nieder,Elizabeth M. Sagatys,Shernan G. Holtan,Nicholas J. Lawrence,Harshani R. Lawrence,Bruce R. Blazar,Claudio Anasetti,Saı̈d M. Sebti,Brian C. Betts	15
6	Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer 2021 ·Nature Communications ·Jeremy McGuire,Jeremy S. Frieling,Chen Hao Lo,Tao Li,(unknown),Harshani R. Lawrence,Nicholas J. Lawrence,Leah M. Cook,Conor C. Lynch	40
7	Inhibition of p53 DNA binding by a small molecule protects mice from radiation toxicity 2020 ·Oncogene ·Qingliang Li,(unknown),(unknown),Mousumi Das,Lihong Chen,Chen Zhang,Harshani R. Lawrence,Gary W. Daughdrill,E. Schönbrunn,Haitao Ji,Jiandong Chen	7
8	Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors 2019 ·Clinical Cancer Research ·Aslamuzzaman Kazi,Shengyan Xiang,Hua Yang,Liwei Chen,Perry Kennedy,Muhammad Ayaz,Steven Fletcher,Christopher T. Cummings,Harshani R. Lawrence,Francisca Beato,Ya’an Kang,Michael P. Kim,Andrea E. Delitto,Patrick W. Underwood,Jason B. Fleming,José G. Treviño,Andrew D. Hamilton,Saı̈d M. Sebti	53
9	Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics 2017 ·Molecular Cancer Therapeutics ·S.W. Ember,Que T. Lambert,Norbert Berndt,Steven Gunawan,Muhammad Ayaz,Marilena Tauro,J. Zhu,Paula J. Cranfill,Patricia Greninger,Conor C. Lynch,Cyril H. Benes,Harshani R. Lawrence,Gary W. Reuther,Nicholas J. Lawrence,E. Schönbrunn	41
10	Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets 2016 ·Cell chemical biology ·Claire E. Knezevic,Gabriëla Wright,Lily L. Remsing Rix,Woosuk Kim,Brent M. Kuenzi,Yunting Luo,(unknown),John M. Koomen,Eric B. Haura,Álvaro N.A. Monteiro,Caius G. Radu,Harshani R. Lawrence,Uwe Rix	77
11	Discovery of PI-1840, a Novel Noncovalent and Rapidly Reversible Proteasome Inhibitor with Anti-tumor Activity 2014 ·Journal of Biological Chemistry ·Aslamuzzaman Kazi,Sevil Özcan,(unknown),Ying Sun,Harshani R. Lawrence,Saı̈d M. Sebti	21
12	ACK1 Tyrosine Kinase Interacts with Histone Demethylase KDM3A to Regulate the Mammary Tumor Oncogene HOXA1 2014 ·Journal of Biological Chemistry ·Kiran Mahajan,Harshani R. Lawrence,Nicholas J. Lawrence,Nupam P. Mahajan	50
13	A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation 2013 ·Cancer Research ·Xiaolei Zhang,Ying Sun,Roberta Pireddu,Hua Yang,(unknown),Harshani R. Lawrence,Wayne C. Guida,Nicholas J. Lawrence,Saı̈d M. Sebti	122
14	Abnormal MDMX degradation in tumor cells due to ARF deficiency 2011 ·Oncogene ·(unknown),Daniele M. Gilkes,Bo Li,Qian Cheng,(unknown),Harshani R. Lawrence,Nicole Lawrence,Jie Chen	26
15	Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs 2010 ·Bioorganic & Medicinal Chemistry Letters ·Latanya M. Scott,Liwei Chen,Kenyon G. Daniel,Wesley H. Brooks,Wayne C. Guida,Harshani R. Lawrence,Saı̈d M. Sebti,Nicholas J. Lawrence,Jie Wu	37
16	Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112 2010 ·Biochemical Pharmacology ·Liwei Chen,(unknown),Latanya M. Scott,Harshani R. Lawrence,Yuan Ren,Yunting Luo,Xin Wu,Shen‐Shu Sung,Wayne C. Guida,Saı̈d M. Sebti,Nicholas J. Lawrence,Jie Wu	31
17	Identification of a disruptor of the MDM2-p53 protein–protein interaction facilitated by high-throughput in silico docking 2009 ·Bioorganic & Medicinal Chemistry Letters ·Harshani R. Lawrence,Zhenyu Li,M.L. Richard Yip,Shen‐Shu Sung,Nicholas J. Lawrence,Mark L. McLaughlin,Gregory J. McManus,Michael J. Zaworotko,Saı̈d M. Sebti,Jiandong Chen,Wayne C. Guida	22
18	A Small-Molecule E2F Inhibitor Blocks Growth in a Melanoma Culture Model 2008 ·Cancer Research ·Yihong Ma,(unknown),Sandhya Boyapalle,Shen‐Shu Sung,Harshani R. Lawrence,Wayne C. Guida,W. Douglas Cress	80
19	Inappropriate Recruitment and Activity by the Src Homology Region 2 Domain-Containing Phosphatase 1 (SHP1) Is Responsible for Receptor Dominance in the SHIP-Deficient NK Cell 2007 ·The Journal of Immunology ·Joseph Wahle,Kim H.T. Paraiso,Robert D. Kendig,Harshani R. Lawrence,(unknown),(unknown),William G. Kerr	42
20	Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor 2006 ·Molecular Pharmacology ·Liwei Chen,Shen‐Shu Sung,M.L. Richard Yip,Harshani R. Lawrence,Yuan Ren,Wayne C. Guida,Saı̈d M. Sebti,Nicholas J. Lawrence,Jie Wu	236

About Harshani R. Lawrence

Harshani R. Lawrence is a scholar working on Oncology, Pharmacology and Hematology, having authored 75 papers that have together received 3.5k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (14 papers), Cancer-related Molecular Pathways (13 papers) and Estrogen and related hormone effects (10 papers). The work is most often cited by research in Toxicology (187 citations), Oncology (1.3k citations) and Immunology (683 citations). Harshani R. Lawrence has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Nicholas J. Lawrence, Saı̈d M. Sebti, Wayne C. Guida, M.L. Richard Yip, Jie Wu, Yunting Luo, Michelle A. Blaskovich, Kiran Mahajan, Nupam P. Mahajan and Richard Jove. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact